Open AccessRisk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study
Author(s) -
Cui Pengfei,
Liu Zhefeng,
Wang Guoqiang,
Ma Junxun,
Qian Yuanyu,
Zhang Fan,
Han Chun,
Long Yaping,
Li Ye,
Zheng Xuan,
Sun Danyang,
Zhang Jing,
Cai Shangli,
Jiao Shunchang,
Hu Yi
Publication year - 2018
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1579
Subject(s) - medicine , pneumonitis , radiation therapy , adverse effect , odds ratio , lung cancer , confounding , case control study , combination therapy , propensity score matching , surgery , lung
Immune checkpoint blockade‐related pneumonitis is a rare but potentially life‐threatening adverse effect, but its risk factors are not completely understood. This case‐control study was conducted to identify pneumonitis risk factors in patients treated with anti‐ PD 1 monoclonal antibodies ( mA bs), including all the patients who developed pneumonitis after anti‐ PD ‐1 mA bs treatment in the Cancer Center of the Chinese People's Liberation Army from September 2015 to September 2017. Two controls per case were matched according to a propensity‐score matching algorithm to account for confounding effects caused by individual baseline variables. Demographic and clinical information was obtained from medical records. In total, 55 cases and 110 controls were included in the study. No association was observed between smoking status or primary lung cancer and risk of pneumonitis. Significant risk factors for pneumonitis related to anti‐ PD ‐1 mA bs were prior thoracic radiotherapy, prior lung disease and combination therapy with odds ratios of 3.34 (1.51‐7.39), 2.86 (1.45‐5.64) and 2.73 (1.40‐5.31), respectively. The associations remained significant in the multivariable logistic regression model. The risk of pneumonitis induced by anti‐ PD ‐1 mA bs is associated with prior thoracic radiotherapy, prior lung disease, and combination therapy. Clinicians should monitor these features in patients receiving anti‐ PD ‐1 therapy to optimize clinical safety and efficacy.